Glucagonoma syndrome: a review and update on treatment
- 16 July 2016
- journal article
- review article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
- Vol. 30 (12), 2016-2022
- https://doi.org/10.1111/jdv.13752
Abstract
Glucagonoma syndrome is defined by the presence of an alpha-cell secreting tumour of the pancreas, elevated levels of glucagon, and a characteristic rash called necrolytic migratory erythema (NME). NME is usually a specific and often initial finding of glucagonoma syndrome, but it may occur in other settings unassociated with an alpha-cell pancreatic tumour (pseudoglucagonoma syndrome). Glucagonoma syndrome must be distinguished from pseudoglucagonoma syndrome. Prompt recognition of NME and subsequent workup for a glucagonoma can allow for an earlier diagnosis and enhance the chances of a favourable outcome. In particular, metastases occur late, so early recognition of glucagonoma syndrome before liver metastases can be life-saving. Surgical resection is the definitive treatment for glucagonoma syndrome, although chemotherapeutic agents, somatostatin analogues and radionuclide therapy are also employed. Herein, we offer an approach to workup after identifying NME and an update on its current treatment modalities.Keywords
This publication has 59 references indexed in Scilit:
- Glucagonoma syndrome: a case reportJournal of Medical Case Reports, 2011
- Pancreatic Endocrine Tumors With Major Vascular Abutment, Involvement, or Encasement and Indication for ResectionArchives of Surgery, 2011
- DAXX / ATRX , MEN1 , and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine TumorsScience, 2011
- Pancreatic endocrine tumors: improved TNM staging and histopathological grading permit a clinically efficient prognostic stratification of patientsLaboratory Investigation, 2010
- Homozygous P86S Mutation of the Human Glucagon Receptor Is Associated With Hyperglucagonemia, α Cell Hyperplasia, and Islet Cell TumorPancreas, 2009
- Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survivalAnnals of Oncology, 2008
- Long-term evaluation of renal toxicity after peptide receptor radionuclide therapy with 90Y-DOTATOC and 177Lu-DOTATATE: the role of associated risk factorsEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Population-Based Study of Islet Cell CarcinomaAnnals of Surgical Oncology, 2007
- Necrolytic migratory erythema without glucagonoma in patients with liver diseaseJournal of the American Academy of Dermatology, 1995
- Glucagonoma syndrome: In vitro evidence that glucagon increases epidermal arachidonic acidJournal of the American Academy of Dermatology, 1984